<i>Epimedium</i> attenuates neuroinflammation and ameliorates Alzheimer's disease through a KAT2B-dependent mechanism.
Overview
Abstract
Background: Alzheimer's disease (AD) is the leading cause of dementia worldwide, yet effective therapies for this neurodegenerative disorder remain scarce. Epimedium, a herb with a history of thousands of years in traditional Chinese medicine, exhibits diverse biological activities and holds potential therapeutic effects against Alzheimer's disease. However, studies on its modern pharmacological mechanisms remain relatively limited.
Methods: TCMSP and PubChem were used to retrieve Epimedium constituents, and SwissTargetPrediction was used to predict potential targets. GeneCards, OMIM, and GEO databases were used to identify targets associated with AD. The AD model was established by intragastric administration of AlCl3 combined with intraperitoneal injection of D-galactose, with the normal saline group serving as controls. Cognitive function was assessed by the Morris water maze, and histopathological changes were observed by H&
Results: We identified 172 key targets, with KAT2B and ACACB determined as core genes through transcriptomic screening. In vivo studies showed that Epimedium significantly ameliorated cognitive deficits and alleviated histopathological damage in hippocampal neurons. Furthermore, Epimedium suppressed neuroinflammation by reducing IL-1β and TNF-α levels and modulated the mRNA expression of key targets (KAT2B, NF-κB) in the hippocampus.
Conclusion: Epimedium improves pathological alterations in the hippocampal tissue and alleviates cognitive and behavioral impairments in rats by modulating neuroinflammation through KAT2B, thereby providing a scientific basis for its potential application and development as a therapeutic agent.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Data links
- ncbi.nlm.nih.gov/
geo , NCBI; found in the acknowledgements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 29 September 2026: the first record
Recorded: type, language, journal, volume, pages, dates, 6 authors, 6 keywords, 1 funder, 47 references.
Cite
This paper
Gao, J., Song, M. L., Liu, J., Jiang, Z., Li, W., & Chen, Y. (2026). &
BibTeX
@article{gao2026lt,
author = {Gao, Jie and Song, Ming Lang and Liu, Jie and Jiang, ZhiBin and Li, Wen and Chen, YunZhi},
title = {{\&
journal = {Frontiers in medicine},
year = {2026},
month = apr,
volume = {13},
pages = {1811410},
publisher = {Frontiers Media SA},
issn = {2296-858X},
doi = {10.3389/
url = {https://
pmid = {42089062},
pmcid = {PMC13135922}
}
RIS
TY - JOUR
AU - Gao, Jie
AU - Song, Ming Lang
AU - Liu, Jie
AU - Jiang, ZhiBin
AU - Li, Wen
AU - Chen, YunZhi
TI - &
T2 - Frontiers in medicine
J2 - Front Med (Lausanne)
PY - 2026
DA - 2026/
VL - 13
SP - 1811410
SN - 2296-858X
PB - Frontiers Media SA
DO - 10.3389/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.3389/
"type": "article-journal",
"title": "&
"container-title": "Frontiers in medicine",
"author": [
{
"family": "Gao",
"given": "Jie"
},
{
"family": "Song",
"given": "Ming Lang"
},
{
"family": "Liu",
"given": "Jie"
},
{
"family": "Jiang",
"given": "ZhiBin"
},
{
"family": "Li",
"given": "Wen"
},
{
"family": "Chen",
"given": "YunZhi"
}
],
"container-title-short":
"volume": "13",
"page": "1811410",
"DOI": "10.3389/
"PMID": "42089062",
"PMCID": "PMC13135922",
"ISSN": "2296-858X",
"publisher": "Frontiers Media SA",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
20
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1186/s13195-026-02075-8
- Physical exercise in combination with audiovisual stimulation alleviates cognitive and affective impairments in Alzheimer's disease model mice via restoring lysosomal membrane integrity.Journal: Alzheimer's research & therapyIn common: Alzheimer's / dementia, cellular / molecular, 3 references
- [2] doi:10.1111/cns.70068
- Neobavaisoflavone Ameliorates Memory Deficits and Brain Damage in Aβ&
lt;sub& gt;25-35& lt;/ sub& gt;-Induced Mice by Regulating SIRT1. Journal: CNS neuroscience & therapeuticsIn common: Alzheimer's / dementia, cellular / molecular, 2 references - [3] doi:10.3389/fnins.2025.1595847
- Expression and potential regulatory mechanism of cellular senescence-related genes in Alzheimer's disease based on single-cell and bulk RNA datasets.Journal: Frontiers in neuroscienceIn common: Alzheimer's / dementia, cellular / molecular, 2 references
- [4] doi:10.3390/ijms27114756
- Multi-Omics Integration and Causal Inference Identify HSD17B1 as a Potential Nobiletin Target Linking Neurosteroid Metabolism to Alzheimer's Disease.Journal: International journal of molecular sciencesIn common: Alzheimer's / dementia, cellular / molecular, 2 references
- [5] doi:10.3390/ijms262010003
- Network-Medicine-Guided Drug Repurposing for Alzheimer's Disease: A Multi-Dimensional Systems Pharmacology Approach.Journal: International journal of molecular sciencesIn common: Alzheimer's / dementia, 2 references
- [6] doi:10.3389/fimmu.2022.986346
- Integrating peripheral blood and brain transcriptomics to identify immunological features associated with Alzheimer's disease in mild cognitive impairment patients.Journal: Frontiers in immunologyIn common: Alzheimer's / dementia, cellular / molecular, 2 references
- [7] doi:10.1038/s41467-026-75862-4 [code]
- Targeting m&
lt;sup& gt;6& lt;/ sup& gt;A writer METTL3 with engineered nanovesicles reduces neuroinflammation in vitro and in vivo. Journal: Nature communicationsIn common: cellular / molecular, 2 references - [8] doi:10.1038/s44318-026-00817-w
- The C9orf72/
SMCR8 complex maintains microglial homeostasis via RAB8A-ESCRT-mediated lysosomal repair. Journal: The EMBO journalIn common: cellular / molecular, 2 references - [9] doi:10.1038/s41514-026-00443-0 [code]
- Network-based discovery of regulatory drivers of cognitive decline in alzheimer's disease.Journal: npj agingIn common: Alzheimer's / dementia, 2 references
- [10] doi:10.1515/med-2026-1477 [code]
- 6PPD-quinone exposure and Alzheimer's disease: insights from integrative network pharmacology, transcriptomics, machine learning, and molecular docking.Journal: Open medicine (Warsaw, Poland)In common: Alzheimer's / dementia, cellular / molecular, 2 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
